Biologic treatments for rheumatoid arthritis

Journal of Orthopaedic Nursing

Volumn 10, Issue 3, 2006, Pages 159-165

  Berrington, Jenny ^a  

^a NOTTINGHAM CITY HOSPITAL   (United Kingdom)

Author keywords

Biologic treatments; Patient care study; Rheumatoid arthritis

Indexed keywords

EID: 33747156628     PISSN: 13613111     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.joon.2006.06.013     Document Type: Article

References (16)

1. Arnett F.C., Edworthy S.M., Block D.A., McShane D.J., Fries J.F., Cooper S.N., Healey L.A., Kaplan S.R., Liang M.H., Luthra H.S., Medsger T.A., Mitchell O.M., Neustadt D.H., Pinals R.S., Schallar J.G., Sharp J.T., Wilder R.L., and Hunder G.G. The American Rheumatism Association 1987: revised criteria for the classification of rheumatoid arthritis. Arthritis and Rheumatism 31 3 (1988) 315-324
2. British Society for Rheumatology, 2000. Guidelines for Prescribing TNF Blockers in Adults with Rheumatoid Arthritis. Report of a working party of the British Society for Rheumatology. BSR, London.
3. British Thoracic Standards of Care Committee. BTS recommendations for assessing risk and managing mycobacterium tuberculosis infection and disease in patients due to start anti-TNF alpha treatment. Thorax 60 (2005) 800-805
4. Cohen J.D., Zaltin S., Kaiser M.J., Bozonnat M.C., Jorgensen C., Daures J., and Sany J. Secondary addition of methotrexate to partial responders to evanescent alone is effective in severe rheumatoid arthritis. Annals Rheumatic Disease 63 (2004) 209-210
5. Frankl E.V. Man's Search for Meaning (1962), Beacon Press, Boston
6. Isenberg D., and Morrow J. Friendly Fire: Explaining Auto-immune Disease (1995), Oxford University Press, Oxford
7. Klareskog L., Van der Heijde D., De Jager J.P., et al. Therapeutic effect of the combination of evanescent and methotrexate compared with each treatment alone in patients with rheumatoid arthritis: double-blind randomised controlled trial. Lancet 363 (2004) 675-681
8. Lipskey P.E., Van der Heijde D.M., St Clair E.W., Furst D.E., Breeveld F.C., Kalden J.R., Smolen J.S., Weisman M., Emery P., Feldman M., Harriman G.R., and Maini R.N. Infliximab and methotrexate in the treatment of rheumatoid arthritis. New England Journal of Medicine 343 22 (2000) 1594-1602
9. National Institute for Clinical Excellence, 2002. Guidance of the use of etanercept and infliximab for the treatment of rheumatoid arthritis. Technology Appraised Guidance No. 36. NICE, London.
10. Oliver S.M. The immune system and new therapies for inflammatory joint disease. Musculoskeletal Care 1 1 (2003) 44-57
11. Prevoo M.L., Van E'Haf M.A., Van Leeuwen M.A., Van De Putte L.B., and Van Riel P.L. Modified disease activity scores that include twenty-eight joint counts. Development and validation in a prospective longitudinal study of patients with rheumatoid arthritis. Arthritis and Rheumatism 38 1 (1995) 44-48
12. Risley S., Thomas MA., and Bray V. Rheumatoid arthritis, new standards of care: nursing implications of infliximab. Journal of Orthopaedic Nursing 8 1 (2004) 41-49
13. Ryan S., Hassell A., Dawes P., and Kendall S. Perceptions of control in patients with rheumatoid arthritis clinical research. Nursing Times 99 13 (2003) 36-38
14. Somerville M. Developing a service for biologic therapies: a personal experience. Musculoskeletal Care 1 1 (2003) 34-43
15. Watson K., and Hyrich K. The role of the British society for rheumatology biologics register (BSRBR) and the NICE guidelines for anti-TNF therapy. Short report. Musculoskeletal Care 1 1 (2003) 58-64
16. Weinblatt M.E., Kremer J.M., Bankhurst A.D., et al. A trial of etanercept, a recombinant tumour necrosis factor receptor: Fc fusion protein, in patients with rheumatoid arthritis receiving methotrexate. New England Journal of Medicine 340 (1999) 253-259